Ustekinumab Patent Expiration
Ustekinumab Large Molecule Patents
Given below is the list of large molecule patents protecting Ustekinumab, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Stelara | USUS10961307 | Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody | Sep 24, 2039 | Janssen Biotech, Inc. |
| Stelara | USUS6902734 | Anti-IL-12 antibodies and compositions thereof |
Sep 25, 2023
(Expired) | Janssen Biotech, Inc. |
| Stelara | USUS8852889 | Cell culture process | Jul 06, 2032 | Janssen Biotech, Inc. |
| Stelara | USUS9217168 | Methods of cell culture | Mar 14, 2033 | Janssen Biotech, Inc. |
| Stelara | USUS9475858 | Cell culture process | Jul 06, 2032 | Janssen Biotech, Inc. |
| Stelara | USUS9663810 | Methods of cell culture | Mar 14, 2033 | Janssen Biotech, Inc. |
Ustekinumab's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List